Clinical trial · Observational
Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia
Genetic Predictors of AML Treatment Response
NCT01024127CI-TRIAL-00022261completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research trial studies deoxyribonucleic acid (DNA) in blood or bone marrow samples from younger patients with acute myeloid leukemia. Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adult Acute Myeloid Leukemia in Remission | Adult Acute Myeloid Leukemia | CURATED_BROADER | 0.78 |
| Childhood Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Laboratory Biomarker Analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ancillary-correlative (predictors of AML treatment outcomes)
- description
- Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.
- interventionNames
- Other: Laboratory Biomarker Analysis
Primary outcomes (2)
- measure
- Incidence of first acute myeloid leukemia relapse
- timeFrame
- Up to 2 years
- measure
- Rate of invasive bacterial infections defined as the number of invasive infection episodes divided by the days at risk
- timeFrame
- From study entry date to completion of therapy date provided on the final Reporting Period case reporting form, assessed up to 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of AML * In remission * Adequate DNA from peripheral blood or bone marrow samples * Concurrent enrollment on CCG-2961, COG-AAML03P1, COG-AAML0531, AML-93, AML-97, AML-04,AML-09, or Canada AML Infection clinical trial required
References
Publications (0)
Data not yet available
No reference posted for this study.